Cosmos Health Participated in Vitafoods Europe 2024; Receives Significant Interest and Numerous New Partnership Inquiries for its Sky Premium Life Nutraceuticals Brand

*CHICAGO, IL / ACCESSWIRE / May 17, 2024 / **Cosmos Health Inc.** ("Cosmos Health" or the "Company'') **(NASDAQ:COSM)*, a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today its successful participation in Vitafoods Europe 2024, the world's leading nutraceutical trade show. The event took place from May 14 to May 16, 2024, at Palexpo in Le Grand-Saconnex, Switzerland.

Vitafoods Europe is renowned for being the premier event in the nutraceutical industry, drawing over 20,000 attendees, more than 50 speakers, 1,100+ exhibitors, and representatives from 160+ countries. The Company showcased its Sky Premium Life range of nutraceuticals, which received significant interest and positive feedback from industry leaders, experts, and potential partners.

During the three-day event, Cosmos Health successfully connected with numerous companies, organizations, and distributors from around the world. The Company's booth, depicted below, attracted a diverse audience eager to learn more about its innovative solutions and products. This platform provided an invaluable opportunity for Cosmos Health to build new partnerships, explore the latest trends in nutraceuticals, and expand its global business network.

*Greg Siokas, Chief Executive Officer of Cosmos Health stated*: "Our participation in Vitafoods Europe 2024 has been a tremendous success. The interest in our Sky Premium Life range was overwhelming, and we are thrilled with the connections we made during the event. This trade show has provided us with a fantastic opportunity to showcase our thought leadership, explore new trends, and accelerate our business growth. We look forward to leveraging the relationships we built to further expand our international presence and continue delivering innovative health solutions."

*About Cosmos Health Inc.*

Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe® and C-Sept®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency, it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X.

Forward-Looking Statements

With the exception of the historical information contained in this news release, the matters described herein, may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements preceded by, followed by, or that otherwise, include the words "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans" and similar expressions or future or conditional verbs such as "will," "should," "would," "may" and "could", are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. These statements, involve unknown risks and uncertainties that may individually or materially impact the matters discussed, herein for a variety of reasons that are outside the control of the Company, including, but not limited to, the Company's ability to raise sufficient financing to implement its business plan, the impact of the COVID-19 pandemic and the war in Ukraine, on the Company's business, operations and the economy in general, and the Company's ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward- looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's filings with the SEC, which are available at the SEC's website (www.sec.gov). The Company disclaims any intention or obligation to update, or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations Contact:

BDG Communications
cosm@bdgcommunications.com
+44 207 0971 653

*SOURCE:* Cosmos Health Inc.
View the original press release on accesswire.com